BioArctic AB Class B (BIOA.B) AI Stock Analysis

• Market Cap: kr25.71B
• Dividend Yield: N/A
• Average Volume (3M): 142.19K
• Price to Earnings (P/E): 25.1
• Beta (1Y): 0.20
• Revenue Growth: 1046.53%
• EPS Growth: N/A
• Country: SE
• Employees: 107
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.10
• Shares Outstanding: 74,241,486
• 10 Day Avg. Volume: 198,890
• 30 Day Avg. Volume: 142,190
• PEG Ratio: -0.04
• Price to Book (P/B): 13.99
• Price to Sales (P/S): 13.76
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 1.84
• Revenue Forecast (FY): kr1.19B

• Rating: 71 Outperform
• Price Target: kr320.00 ▲(3.36% Upside)
• Action: Reiterated Date: 02/20/26
• Date: Action: Reiterated 02/20/26

The score is driven primarily by the strong 2025 financial inflection and a conservative balance sheet, tempered by historically volatile profitability/cash generation and uncertain free-cash-flow durability. Technicals are supportive with an established uptrend, while valuation (P/E ~30) is a meaningful headwind.

Positive Factors

Conservative balance sheet, low leverage

Very low leverage and a materially larger equity base provide durable financial flexibility to fund development, absorb trial setbacks, and pursue partnerships without immediate refinancing. This reduces insolvency risk and preserves strategic optionality across multiple development paths.

Sharp 2025 profitability inflection and high margins

A step-change to very high gross and net margins suggests the company can capture licensing or royalty economics efficiently. If sustained, such margin structure supports reinvestment in R&D, funds partner-enabled development, and improves long-term return on equity and cash available for strategic uses.

Partner-driven licensing model (Eisai/lecanemab)

A business model focused on licensing and partnering materially reduces late-stage commercialization capital needs and shifts execution risk to larger pharma partners. Milestone and royalty streams create scalable, capital-efficient upside and align incentives for co-development and market access.

Negative Factors

Historically volatile profitability and earnings

Episodic swings between losses and profits indicate earnings depend on timing of milestones and one-off items rather than stable recurring revenue. This volatility undermines forecasting, complicates capital planning, and raises the risk that recent profits may not persist absent repeatable revenue streams.

Uncertain cash conversion; zero free cash flow in 2025

Zero reported free cash flow despite strong operating cash implies heavy investments or working capital timing; combined with prior negative FCF years, this creates uncertainty about durable cash available for R&D, shareholder returns, or buffering setbacks without new financing or partner funding.

Revenue concentration and milestone dependency

Dependence on a single large partner and milestone-triggered payments creates concentration and lumpy receipts. Regulatory, commercial, or timing setbacks at the partner can sharply reduce BioArctic's income, impairing planning and making long-term revenue visibility and independent growth harder to achieve.

BioArctic AB Class B Business Overview & Revenue Model

Company Description

BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.

How the Company Makes Money

BioArctic generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties on sales of developed products. The company's revenue model is built on the successful advancement of its drug candidates through clinical trials, leading to licensing agreements or joint ventures. Additionally, BioArctic may receive funding through grants or public funding aimed at supporting research in biotechnology and neurodegenerative disease therapies. The company's strategic collaborations with industry leaders enhance its financial position and expand its market reach, contributing to its overall earnings.

BioArctic AB Class B Financial Statement Overview

Summary

Strong 2025 inflection with sharply improved profitability (very high gross and net margins) and a low-leverage balance sheet. However, results and cash flows have been volatile across prior years, and free cash flow is reported as zero in 2025, which limits confidence in durability and cash conversion.

Income Statement

Profitability improved sharply in 2025, with very strong margins (gross margin ~97%, net margin ~51%) and a swing from a large loss in 2024 to meaningful profits in 2025. Revenue also accelerated dramatically versus the prior year, indicating a step-change in the business. Offsetting this, results have been volatile across the period (losses in 2024, 2022, 2021, 2020), suggesting earnings may be driven by timing/milestones rather than a smooth, recurring growth profile.

Balance Sheet

The balance sheet looks conservative, with low leverage (debt-to-equity ~0.04 in 2025) and a large equity base that has grown materially versus 2024. Returns on equity are very strong in 2025 (~52%), reflecting the profit surge. Key watch-outs are the variability in profitability year-to-year (which can pressure equity if losses recur) and the increase in absolute debt versus earlier years, even though leverage remains low.

Cash Flow

Cash generation rebounded strongly in 2025, with operating cash flow well above net income (about 2.7x), which is a clear positive for earnings quality. However, free cash flow is reported as zero in 2025 (down from positive in 2023 and negative in 2024), creating uncertainty around how much cash is truly left after investment needs. The historical pattern is uneven—negative operating and free cash flow in 2024 and 2022—so cash conversion and reinvestment requirements appear volatile.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.00B	257.35M	616.00M	228.29M	23.15M
Gross Profit	1.94B	230.37M	526.37M	153.97M	-31.92M
EBITDA	1.38B	-165.13M	295.29M	4.03M	-126.42M
Net Income	1.02B	-177.08M	229.25M	-11.18M	-119.79M
Balance Sheet
Total Assets	2.58B	1.11B	1.19B	858.31M	897.73M
Cash, Cash Equivalents and Short-Term Investments	2.19B	778.92M	1.11B	805.39M	848.40M
Total Debt	72.42M	54.23M	4.98M	10.04M	15.88M
Total Liabilities	608.14M	216.74M	139.50M	72.06M	109.05M
Stockholders Equity	1.97B	894.94M	1.05B	786.24M	788.68M
Cash Flow
Free Cash Flow	0.00	-342.97M	302.25M	-44.38M	-144.84M
Operating Cash Flow	1.43B	-316.33M	309.69M	-31.64M	-140.46M
Investing Cash Flow	-894.65M	205.63M	-507.49M	-12.76M	-4.41M
Financing Cash Flow	26.91M	5.69M	14.06M	-2.81M	-7.39M

BioArctic AB Class B Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 309.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOA.B, the sentiment is Negative. The current price of 309.6 is below the 20-day moving average (MA) of 322.46, below the 50-day MA of 321.11, and above the 200-day MA of 267.21, indicating a neutral trend. The MACD of -1.61 indicates Positive momentum. The RSI at 41.54 is Neutral, neither overbought nor oversold. The STOCH value of 7.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BIOA.B.

BioArctic AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIOA.B	71 Outperform	kr25.71B	25.09	68.77%	―	1046.53%	―
HNSA	56 Neutral	kr3.14B	-4.79	―	―	-5.69%	21.58%
CANTA	55 Neutral	€1.07B	7.27	81.19%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BINV	47 Neutral	kr1.42B	-4.27	-36.52%	―	533.73%	20.92%
VICO	44 Neutral	kr2.94B	-5.25	-71.87%	―	-91.85%	-6.65%
XSPRAY	44 Neutral	kr1.01B	-5.47	-35.03%	―	―	25.14%

BioArctic AB Class B Corporate Events

BioArctic Updates Share Count After Stock Option Exercise

BioArctic AB has issued 78,000 new Class B shares in February 2026 to fulfill commitments under its 2019/2028 stock option program, providing equity-based incentives to participants. Following this issuance, the company’s total share count stands at 88,719,485, split between 74,319,489 listed Class B shares and 14,399,996 unlisted Class A shares, underscoring a dual-class structure that concentrates voting power.

The A shares each carry ten votes compared with one vote per B share, bringing the total number of votes in the company to 218,319,449 and maintaining significant control with A share holders. This capital structure update, disclosed under EU Market Abuse Regulation requirements, offers investors and other stakeholders an updated view of BioArctic’s share base and governance dynamics as it advances its neurodegenerative disease portfolio.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK385.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic Enters “Growth Era” on Record 2025 and Expanding Leqembi Reach

BioArctic reported a transformative 2025, driven by rapid global expansion of Alzheimer’s therapy Leqembi through partner Eisai and record financial results that doubled its cash position. Leqembi, including the new subcutaneous Leqembi Iqlik version, gained approvals or launches across major markets such as the U.S., Japan, China, Brazil, Canada, the U.K. and others, with priority reviews underway in key territories and growing patient uptake despite pricing and inventory headwinds.

Fourth-quarter net revenues rose sharply, supported by a 31 percent increase in Leqembi royalty income and new income from a Novartis agreement, though quarterly profit was slightly negative while cash flow from operations was strong. The company’s board proposed a dividend for 2025, and management emphasized that the strengthened balance sheet will support an expanded R&D push, including new projects in Huntington’s and Parkinson’s disease, candidate nominations in ALS and Parkinson-related disorders, and continued investment in its BrainTransporter platform to attract additional strategic partnerships.

BioArctic advanced multiple pipeline assets, with Phase 2a trials for exidavnemab in Parkinson’s disease and multiple system atrophy progressing toward completion in 2026 and planning already underway for Phase 2b. Management framed 2025 as the beginning of a “growth era,” in which robust Leqembi royalties, broader market penetration and a deeper neurology pipeline are expected to underpin the company’s long-term growth and enhance its standing as a key innovator in neurodegenerative disease treatments.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK387.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic Sets February 18 Release and Investor Call for Q4 2025 Report

BioArctic will publish its fourth quarter report for October to December 2025 on February 18, 2026, at 08:00 a.m. CET, underscoring a key financial update for investors in the fast-evolving neurodegenerative disease treatment space. The company will host a presentation and Q&A at 09:30 a.m. CET the same day, accessible via webcast and teleconference and later available on its website, signaling an effort to maintain active dialogue and transparency with investors, analysts, and media as it advances its portfolio around Leqembi and other pipeline assets.

The results briefing, led by CEO Gunilla Osswald and CFO Anders Martin-Löf, will provide stakeholders with insight into BioArctic’s operational and financial progress over the quarter. Given BioArctic’s pivotal role in Alzheimer’s treatment through Leqembi and its broader pipeline, the upcoming report and management commentary may offer important indications on commercialization dynamics, R&D momentum, and the company’s positioning within the competitive neurodegenerative therapeutics market.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK387.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic’s Partner Eisai Wins Priority Review in China for At-Home Leqembi Alzheimer’s Injection

BioArctic’s partner Eisai has secured Priority Review status in China for a Biologics License Application covering a subcutaneous autoinjector formulation of Leqembi for early Alzheimer’s disease. The move builds on Leqembi’s 2024 launch in China’s private market and its inclusion in the new Commercial Insurance Innovative Drug List, which is expected to support broader access via commercial insurance products.

If approved, the once-weekly at-home subcutaneous dosing could offer a more convenient alternative to current intravenous infusions, easing pressure on hospital resources and potentially streamlining Alzheimer’s care pathways in a country with an estimated 17 million people living with mild cognitive impairment or mild dementia due to the disease. The application reinforces BioArctic and Eisai’s global strategy for Leqembi, which already includes broad regulatory approvals, ongoing Phase 3 and preclinical Alzheimer’s studies, and parallel efforts to expand subcutaneous options in the U.S., Japan and other markets.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK387.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic Royalty Income Climbs on Rising Global Sales of Alzheimer’s Drug Leqembi

BioArctic reported that partner Eisai generated JPY 20.7 billion in global sales of Alzheimer’s drug Leqembi in the fourth quarter of 2025, resulting in SEK 127 million in royalties for BioArctic, a year-on-year increase of about 31 percent, with underlying growth closer to 50 percent at constant exchange rates. The figures underscore the accelerating commercial traction and expanding geographic footprint of Leqembi—including multiple regulatory approvals, broader dosing options and inclusion on China’s Commercial Insurance Innovative Drug List—strengthening BioArctic’s royalty-based revenue stream and reinforcing its strategic positioning in disease-modifying Alzheimer’s therapies ahead of upcoming earnings disclosures from Eisai and BioArctic later in February.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK387.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

Eisai Seeks EU Approval for Monthly Leqembi Maintenance Dosing, Enhancing BioArctic’s Alzheimer’s Franchise

Eisai, BioArctic’s long-standing partner, has submitted a Marketing Authorisation Variation to the European Medicines Agency to allow a once-every-four-weeks intravenous maintenance dosing regimen for Alzheimer’s drug Leqembi (lecanemab), following an initial 18‑month period of biweekly infusions in patients with early-stage disease. The move, which aligns the EU regimen with maintenance dosing already approved in major markets such as the U.S., U.K. and China and complements a growing portfolio of subcutaneous formulations and ongoing late-stage trials, underscores BioArctic’s strengthening position in disease-modifying Alzheimer’s therapies and could expand treatment convenience and uptake, bolstering future royalty and milestone revenue potential for the Swedish biotech as it prepares joint commercialization with Eisai in the Nordic region.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK387.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic and Eisai Win FDA Priority Review for At‑Home Leqembi Autoinjector Start Dosing

BioArctic’s partner Eisai has secured U.S. FDA Priority Review for a supplemental Biologics License Application covering a new subcutaneous starting dose of Leqembi Iqlik, delivered via a weekly autoinjector, for patients with early-stage Alzheimer’s disease, with a decision expected by May 24, 2026. If cleared, the regimen would make Leqembi the first anti‑amyloid therapy to offer fully at-home initiation and maintenance dosing, potentially easing treatment burden for patients and caregivers, reducing reliance on infusion centers and associated healthcare resources, and further strengthening Leqembi’s competitive position in the rapidly evolving Alzheimer’s therapy market.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK387.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic Partner Eisai Wins China Review of At‑Home Leqembi Injection for Early Alzheimer’s

BioArctic’s partner Eisai has had its Biologics License Application accepted by China’s National Medical Products Administration for a subcutaneous autoinjector formulation of Leqembi (lecanemab) for early Alzheimer’s disease, positioning the drug to potentially become the first anti-amyloid therapy in China that can be self-administered at home from treatment initiation. The weekly at-home SC dosing is intended to offer a more convenient alternative to hospital-based IV infusions, potentially easing pressure on healthcare resources in a country where Eisai estimates 17 million people were living with mild cognitive impairment or mild dementia due to Alzheimer’s in 2024, and its progress adds to Leqembi’s growing global regulatory and reimbursement footprint, which underpins BioArctic’s future royalty streams and its planned joint commercialization with Eisai in the Nordic market.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic’s Leqembi Gains Inclusion in China’s Innovative Drug List

BioArctic AB’s partner Eisai announced that Leqembi® has been included in China’s ‘Commercial Insurance Innovative Drug List,’ a significant step towards expanding access to early Alzheimer’s Disease treatment in China. This inclusion is expected to bridge the gap between basic reimbursement systems and innovative medicines, potentially impacting the company’s market presence and offering new opportunities for stakeholders.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic’s Lecanemab Shows Promise in Delaying Alzheimer’s Progression

BioArctic AB’s partner Eisai presented promising data at the CTAD 2025 conference indicating that continued treatment with lecanemab (Leqembi®) could delay the progression of Alzheimer’s disease by up to 8.3 years in certain patient groups. The findings suggest that early initiation of treatment may significantly slow disease progression, offering hope for improved patient outcomes. Additionally, the subcutaneous formulation of lecanemab, approved for use in the U.S. and under review in Japan, demonstrated bioequivalence to intravenous dosing, maintaining efficacy and safety while offering a more convenient administration option.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.